Pharma Giants’ Bold Move Shocks Drug Industry

Vials and blister packs of pills on table

Can a pill that prevents strokes also revolutionize drug pricing by cutting out the middleman?

At a Glance

Bristol Myers Squibb and Pfizer introduce a direct-to-patient program for Eliquis.
The program offers over 40% discount to eligible cash-paying patients.
Launch aims to improve access and affordability, bypassing traditional pharmacy channels.
Potential industry shift towards more direct-to-patient models for high-cost drugs.

Eliquis: A Game-Changer in More Ways Than One

In the world of pharmaceuticals, where the price tag can often be as daunting as the disease, Bristol Myers Squibb and Pfizer are making waves with their recent decision to sell the blood thinner Eliquis directly to patients. Eliquis, known for its prowess in reducing stroke risk, is now stepping into the spotlight again—not for its medical benefits, but for its groundbreaking sales approach. This move is poised to shake up the pharmaceutical industry by offering a direct-to-patient purchasing program that slashes prices by more than 40% for those paying out of their own pockets.

This initiative, aptly named the Eliquis 360 Support Program, is designed to cater to the uninsured or underinsured patients who have been pinching pennies to afford their medications. Instead of relying on traditional pharmacy and insurance channels, eligible patients can now purchase Eliquis directly at a fraction of the price. The program launched on July 17, 2025, and is already being hailed as a potential game-changer for drug pricing models, setting a precedent for other high-cost medications.

The Power Players Behind the Curtain

The collaboration between Bristol Myers Squibb and Pfizer dates back to 2007, when they joined forces to commercialize Eliquis. With a shared vision and a 60/40 profit split favoring Pfizer, the two pharmaceutical giants have dominated the market for direct oral anticoagulants since Eliquis received FDA approval in 2012. Despite facing patent litigation that delayed the entry of generic competitors, the companies have maintained a stronghold on the market, with Eliquis emerging as a leading player.

The decision to launch the Eliquis 360 program reflects the companies’ strategic response to growing pressure from regulators and the public to address the high cost of drugs. By bypassing pharmacy benefit managers and offering direct access to patients, Bristol Myers Squibb and Pfizer are not only making a statement about affordability but also reinforcing their commitment to patient-centered care.

Who Stands to Benefit—and Who Might Be Left Out

The primary beneficiaries of the Eliquis 360 Support Program are cash-paying patients who previously faced the daunting task of affording Eliquis without insurance coverage. By offering a substantial discount, the program aims to improve medication adherence and health outcomes for these patients, who often struggle to keep up with high drug costs. For Bristol Myers Squibb and Pfizer, this move could boost their reputation and increase direct sales volume among uninsured patients.

However, the program’s impact may be limited by its eligibility criteria, which restricts discounts to cash-paying patients. Those with insurance or government coverage are not included, potentially leaving some patients without relief from high out-of-pocket costs. As the program unfolds, healthcare providers may need to adjust prescribing practices and support patients in navigating this new landscape.

A Glimpse into the Future of Drug Pricing

The Eliquis 360 initiative could have far-reaching implications for the pharmaceutical industry. If successful, it may inspire other companies to explore direct-to-patient models, challenging the traditional roles of pharmacy benefit managers and insurers. This shift could lead to increased transparency and more competitive pricing for high-cost drugs, ultimately benefiting patients.

While some experts praise the program for addressing a critical gap in patient access, others caution that it does not tackle the underlying issues of high drug prices and insurance coverage gaps. As the industry grapples with these complex challenges, the Eliquis 360 program offers a glimpse into a potential future where patients have more direct access to the medications they need, at prices they can afford.